← All trials
NCT04934475
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 1, 2021
- Primary completion
- Sep 1, 2024
- Completion date
- Sep 1, 2028
- First posted
- Jun 22, 2021
- Last posted
- Jun 22, 2021
- Enrollment
- 716
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Intergroupe Francophone du MyelomeLead sponsor
- AmgenCollaborator
- University of NantesOverall official - principal investigator
- SanofiCollaborator
- University of NantesOfficial
- Bristol-Myers SquibbCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.